The anticoagulant warfarin was prescribed to more than one million persons in the US in 2006. Warfarin effectively prevents coagulation and is used to treat patients who are at increased risk for thromboembolic events (1 ) . Individual responses to warfarin therapy can vary greatly, and these differing responses have a genetic basis that has been recognized for many years (2, 3 ) .
Pharmacogenetics is the study of genetic differences and their effects on drug metabolism. The application of pharmacogenetics in identifying individuals with the polymorphisms that produce various responses in patients and the concomitant adjustment of their warfarin dose is expected to confer substantial benefit to patients and to the healthcare system overall. Improved patient safety and reduction in healthcare costs can be realized by decreasing the time required to achieve a stable international normalized ratio, thereby decreasing the risk of adverse events and the length of hospitalization for some patients. The importance of this initiative is underscored by its inclusion in the Critical Path Initiative of the US Food and Drug Administration (4 ) as an example of patient-tailored therapies. In addition, the US Food and Drug Administration recently mandated the inclusion of a warning label on warfarin packaging recommending pharmacogenetic testing for patients starting such therapy (5 ) .
Studies of heterogeneity in patient sensitivity to warfarin have led to identification of at least 2 genes that contribute to differential responses in patients. These genes, cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) 5 and vitamin K epoxide reductase subunit protein 1 (VKORC1), contribute approximately 60% to this difference (6, 7 ) . There are 2 clinically important alleles of CYP2C9 [2C9*2 (430C3 T) and 2C9*3 (1075A3 C)] and 1 for VKORC1 (Ϫ1639 G3 A) with demonstrated effects on warfarin metabolism (4 ). In addition, another recently described polymorphism in the gamma-glutamyl carboxylase (GGCX) gene, 1181T3 G, has demonstrated a modest yet significant effect on warfarin metabolism (8 ) . Because the GGCX gene product is immediately downstream of the VKORC1 gene product in warfarin metabolism, and its genetic variation contributes mildly to the warfarin response, we included this in our panel.
We sought to design a multiplexed assay allowing for the interrogation of these 4 single-nucleotide polymorphisms (SNPs) in a single sample. Primers for PCR of the appropriate gene fragments were used for amplification, in a single plex or multiplex format. Subsequently, SNP interrogation oligonucleotides were used to query the allele of interest, with the antisense strands being investigated for the 4 SNPs. Unlabelled oligonucleotides of varying sizes were designed to flank the SNP of interest and were subsequently extended by 1 base with base terminator. This entire reaction was per-formed in solution. In the final step, the multiplexed SNP reaction was separated by capillary electrophoresis, and a window of 10 -90 bp was visualized. Because each of the bases was labeled with a different color fluorophore, we readily detected the allele on the basis of peak size and color.
Genomic DNA was isolated from whole blood by using the QIAamp DNA mini kit (Qiagen) according to manufacturer's instructions. Primer3 software (http://frodo.wi.mit.edu) was used to design primers to amplify fragments of 200 -700 bp surrounding the SNP of interest. Details for each of the PCR primers are listed in Table 1 ; they were amplified simultaneously in a single multiplex reaction. In a total reaction volume of 40 L, the final concentration for each component was as follows: 50 nmol/L of each forward and reverse primer, 200 nmol/L dNTPs, 100 ng genomic DNA, 10ϫ reaction buffer [100 mmol/L Tris-HCl (pH 8.6), 500 mmol/L KCl, 15 mmol/L MgCl 2 ], nuclease-free water, and 0.5 L Taq Polymerase (5 U/L; USB). Samples were subject to these cycling parameters: denaturation at 95°C for 10 min, 35 cycles of 94°C for 30 s, 55°C for 30 s, and 68°C for 1 min, followed by 4°C hold. Each primer set amplified a single fragment, and the multiplex reaction produced 4 bands comigrating with the appropriate singlet bands (Fig. 1) . The SNP oligonucleotide extension reaction was performed in a 10-L reaction volume comprised of 4 L SNPStart MasterMix, 1 L of nuclease-free PCR-grade water, 5 mol/L (final concentration) of each SNP interrogation primer (from 100 mol/L mix), and 2 L PCR product. The SNP interrogation oligonucleotides were of different lengths (Table 1) , and after capillary electrophoresis, resolved and manifested as distinct peaks of the appropriate size (Fig. 1) .
Our multiplexed SNP interrogation assay was used for the simultaneous detection of these 4 alleles in a single reaction, and entailed these steps: (a) PCR amplification of the target gene fragment and removal of deoxynucleotides and primers by using exonucleaseshrimp alkaline phosphatase (ExoSAP-IT, GE HealthCare); (b) inactivation of exonuclease-shrimp alkaline phosphatase; (c) hybridization of SNP oligonucleotide ending 1 base from the SNP of interest and single-base extension to allow incorporation of a fluorophorespecific chain-terminating nucleotide, by using the SNPStart Kit (Beckman Coulter), and subsequent removal of any excess dye with additional shrimp alkaline phosphatase (SAP, GE HealthCare); and (d) capillary electrophoresis separation of the fragments on a GeXP genetic analysis system (Beckman Coulter). We tested samples containing the various polymorphisms of interest (2C9*2 and 2C9*3, VKORC1, and GGCX) to confirm the correct genotype, and a single peak at the expected size was detected. We assayed all samples using this reaction and compared the results with results from automated sequencing performed with an ABI 3730 (University of California at Los Angeles Sequencing Facility), with the appropriate primers (Table 1) . We tested a set of known positive samples and also a set of 24 unknown samples. The GGCX SNP exhibits a low allele frequency and therefore, as expected, was not detected in our small cohort.
Our assay can be performed within a 5-h turnaround time with minimal hands-on effort, after extraction of genomic DNA. We observed 100% concordance on 24 samples when we compared our assay with traditional DNA sequencing (see Supplemental Table 1 in the Data Supplement that accompanies the online version of this Brief Communication at http://www. clinchem.org/content/vol55/issue4). This assay can be used for high-throughput screening of patient samples, allowing for analysis of two 96-well plates on a single overnight run. It can be employed to assess a patient's genotype with regard to each of these alleles. Because these alleles have demonstrated clinical significance in warfarin metabolism, it is important to identify patients with these polymorphisms who will be enrolled for treatment in warfarin-containing regimens.
Genotyping patients before initiation of therapy or during the first few days of starting a regimen would help determine the appropriate drug dose and improve the likelihood of achieving a stable international normalized ratio, thus reducing adverse events. Our mul- 
